Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Rodman & Renshaw

Stock analysts at Rodman & Renshaw assumed coverage on shares of Eupraxia Pharmaceuticals (NASDAQ:EPRX) in a research note issued to investors on Thursday, MarketBeat reports. The brokerage set a “buy” rating and a $9.00 price target on the stock. Rodman & Renshaw’s target price suggests a potential upside of 187.48% from the company’s current price.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ EPRX opened at $3.13 on Thursday. The stock has a market cap of $85.41 million and a P/E ratio of -4.35. Eupraxia Pharmaceuticals has a fifty-two week low of $2.20 and a fifty-two week high of $5.58. The stock has a 50 day simple moving average of $2.66 and a two-hundred day simple moving average of $2.68.

Institutional Trading of Eupraxia Pharmaceuticals

A hedge fund recently bought a new stake in Eupraxia Pharmaceuticals stock. 180 Wealth Advisors LLC bought a new position in Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 13,000 shares of the company’s stock, valued at approximately $34,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company’s lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee.